Most Popular - Enanta Pharmaceuticals (ENTA) IPO’d in March but remains virtually flat following an initial spike in share price. In our view, the stock is quite cheap … Continue Reading
Read NowLong Ideas - Curis (CRIS) has been around for quite some time with little to show for it but a significant long-term loss and some dud product candidates. … Continue Reading
Read NowRecap - Darapladib failed two mid-stage studies in 2008, yet GlaxoSmithKline (GSK) moved the cardiovascular drug into Phase III trials nonetheless. While most investors consider the large … Continue Reading
Read NowMost Popular - Medivation (MDVN) has made a rapid come-back since investors exited en masse in mid-June as the company’s closest development-stage competitor was bought by J&J (JNJ). … Continue Reading
Read NowRecap - Split-adjusted, Ohr Pharma (OHRP) is up 61% since PropThink covered the small-cap drug developer in mid-March. Some investors remain skeptical of the company’s lead asset, … Continue Reading
Read NowMost Popular - Shares of TG Therapeutics (TGTX) had a rough end to last week and a worse beginning to this week. But it was that weakness that … Continue Reading
Read NowMost Popular - The FDA accepted Durect’s (DRRX) New Drug Application for Posidur on Thursday, causing shares to gap up and continue higher through the day. Analysts expect … Continue Reading
Read Now